Evidence map›Paper›PMID 40812313›Full record

ArticleMolecular cell2025

Ubiquitination of the histone variant mH2A1.2 prevents toxic RAD18 accumulation at a subset of genomic loci upon replication stress.

Maxime Galloy, Andréanne Blondeau, Élodie Vion, Daein Kim, Collin A Bakker, Vincent Gaggioli, Mélissa Thomas, Élise G Lavoie, Isabelle Marois, Alberto David Delgado Monterroso and 5 more

Abstract read
In one paragraph

Article in Molecular cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Maxime GalloyDepartment of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec, QC G1V 0A6, Canada; Oncology Division, CHU de Québec-Université Laval Research Center, Québec, QC G1J 0J9, Canada; Université Laval Cancer Research Centre and Regroupement Québécois de Recherche sur la Fonction, L'ingénierie et les Applications des Protéines (PROTEO), Québec, QC, Canada.
Andréanne BlondeauOncology Division, CHU de Québec-Université Laval Research Center, Québec, QC G1J 0J9, Canada; Université Laval Cancer Research Centre and Regroupement Québécois de Recherche sur la Fonction, L'ingénierie et les Applications des Protéines (PROTEO), Québec, QC, Canada.
Élodie VionDepartment of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec, QC G1V 0A6, Canada; Oncology Division, CHU de Québec-Université Laval Research Center, Québec, QC G1J 0J9, Canada; Université Laval Cancer Research Centre and Regroupement Québécois de Recherche sur la Fonction, L'ingénierie et les Applications des Protéines (PROTEO), Québec, QC, Canada.
Daein KimDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
Collin A BakkerDepartment of Molecular Genetics and the Oncode Institute, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam 3015GD, the Netherlands.
Vincent GaggioliDepartment of Molecular Genetics and the Oncode Institute, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam 3015GD, the Netherlands.
Mélissa ThomasDepartment of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec, QC G1V 0A6, Canada; Oncology Division, CHU de Québec-Université Laval Research Center, Québec, QC G1J 0J9, Canada; Université Laval Cancer Research Centre and Regroupement Québécois de Recherche sur la Fonction, L'ingénierie et les Applications des Protéines (PROTEO), Québec, QC, Canada.
Élise G LavoieDepartment of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec, QC G1V 0A6, Canada; Université Laval Cancer Research Centre and Regroupement Québécois de Recherche sur la Fonction, L'ingénierie et les Applications des Protéines (PROTEO), Québec, QC, Canada.
Isabelle MaroisFaculty of Sciences, Department of Biology, Université de Sherbrooke, and CHUS Research Center and Cancer Research Institute, Sherbrooke, QC J1K 2R1, Canada.
Alberto David Delgado MonterrosoFaculty of Sciences, Department of Biology, Université de Sherbrooke, and CHUS Research Center and Cancer Research Institute, Sherbrooke, QC J1K 2R1, Canada.
Jean-Yves MassonDepartment of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec, QC G1V 0A6, Canada; Oncology Division, CHU de Québec-Université Laval Research Center, Québec, QC G1J 0J9, Canada; Université Laval Cancer Research Centre and Regroupement Québécois de Recherche sur la Fonction, L'ingénierie et les Applications des Protéines (PROTEO), Québec, QC, Canada.
Nitika TanejaDepartment of Molecular Genetics and the Oncode Institute, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam 3015GD, the Netherlands.
Kyle M MillerDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30307, USA.
Alexandre MaréchalFaculty of Sciences, Department of Biology, Université de Sherbrooke, and CHUS Research Center and Cancer Research Institute, Sherbrooke, QC J1K 2R1, Canada.
Amélie Fradet-TurcotteDepartment of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec, QC G1V 0A6, Canada; Oncology Division, CHU de Québec-Université Laval Research Center, Québec, QC G1J 0J9, Canada; Université Laval Cancer Research Centre and Regroupement Québécois de Recherche sur la Fonction, L'ingénierie et les Applications des Protéines (PROTEO), Québec, QC, Canada. Electronic address: amelie.fradet-turcotte@crchudequebec.ulaval.ca.

Funding

Shaping DNA Damage Response Networks Via Histone H2A VariantsR01CA198279 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI Kyle M Miller · 2016 to 2026
$3.3M
Mechanisms of Endogenous DNA Damage PromotionR01CA250905 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MILLER, KYLE M, ROSENBERG, SUSAN M · 2020 to 2024
$3.3M
NCI NIH HHS R01 CA198279NCI NIH HHS R01 CA250905
6 · The paper itself

Abstract

Spatiotemporal recruitment of DNA repair factors is crucial to coordinate repair across DNA lesions. MacroH2A1.2 (mH2A1.2), which accumulates in subgenomic regions that are difficult to replicate (e.g., common fragile sites, telomeres, and repeated sequences), selectively promotes homology-driven DNA repair; however, the mechanisms remain elusive. We report an unexpected role for RNF168-mediated mH2A1.2 ubiquitination in preventing aberrant RAD18 recruitment to subgenomic loci experiencing prolonged replication arrest in human cancer cells. Biochemical reconstitution revealed that RAD18 cannot bind ubiquitinated mH2A1.2-containing nucleosomes. In cells, loss of mH2A1.2 ubiquitination increases RAD18 and γH2AX levels at collapsed forks and sensitizes cells to replication stress. Depletion of RAD18, fork remodelers, or the endonuclease MUS81 rescues these phenotypes, indicating that mH2A1.2-ubiquitination prevents toxic RAD18 engagement at MUS81-dependent double-strand breaks (DSBs), which arise at collapsed forks in difficult-to-replicate sites experiencing prolonged arrest. Our findings highlight the detrimental consequences of inappropriate DNA processing by MUS81 at these loci.

Indexed as

DNA-Binding ProteinsDNA ReplicationHistonesCell Line, TumorDNA Breaks, Double-StrandedDNA RepairEndonucleasesHeLa CellsHumansNucleosomesUbiquitinationUbiquitin-Protein LigasesDNA-Binding ProteinsEndonucleasesH2AX protein, humanHistonesMUS81 protein, humanNucleosomesRAD18 protein, humanRNF168 protein, humanUbiquitin-Protein Ligases53BP1chromatinE3 ubiquitin ligase RNF168histone H2A varianthistone mH2A1.2MUS81RAD18replication stressRNF169single-ended double-strand break

Identifiers

PMID40812313
PMCPMC12519460

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.